The NCTN's Alliance for Clinical Trials in Oncology (Alliance) represents a merger of three former NCI-funded cancer cooperative groups (ACOSOG, CALGB, and NCCTG). Combined, these groups and their associated biorepositories represent an unequaled resource of expertise, institutional infrastructure, and high quality, densely annotated patient biospecimens collected from several decades of cancer therapeutic trials. The scientific mission of the Alliance Biorepository and Biospecimen Resource (ABBR) is to support the activities of the Alliance, the NCTN, and the broader cancer research community through four specific aims, which are: 1) To prospectively support Alliance and NCTN-wide clinical cancer trials with respect to biospecimen procurement, tracking, processing, quality assurance, storage, and distribution. The ABBR will develop approaches to streamline biospecimen collection and support the collection of novel biospecimen types for genomic- and proteomic-based biomarker studies in the context of therapeutic trials; 2) To provide a resource of high quality, densely annotated biospecimens for secondary correlative science studies directed toward biomarker validation with high clinical impact. The ABBR will work with other NCTN biorepositories, the NCTN Biospecimen `Front Door Service', and the NCTN Navigator tool to provide inventories of biospecimens that may be suitable for secondary correlative science studies proposed both within the NCTN groups as well as the broader cancer research community. It will also work with other NCTN members and NCI to create an efficient and transparent process for reviewing, approving, and executing such requests so as to speed the translation of candidate biomarkers to cancer diagnostics with clinical utility; 3) To provide scientific leadership to the NCTN biobanking enterprise, by active participation in the NCTN Group Banking Committee (GBC). The ABBR will continue its outstanding commitment to harmonizing and improving biobanking Best Practices by active participation in GBC meetings, subcommittee's activities, and work products, and; 4) To provide expertise and infrastructure support for biobanking efforts beyond the NCTN, including NCI's Experimental Therapeutics Clinical Trials Network (ETCTN) and the Community Oncology Research Program (NCORP). By creating a federated infrastructure of biorepository sites and a unifying informatics platform for tracking biospecimens across them, the ABBR is uniquely poised to collaborate with other NCI programs, whenever biorepository or biospecimen resources are required for specific translational cancer research efforts.

Public Health Relevance

The mission of the Alliance Biorepository and Biospecimen Resource (ABBR) is to safeguard and facilitate the use of patient tissue and fluid biospecimens for practice changing cancer research. The ABBR helps to collect, process, and store biospecimens from patients enrolled on NCTN Alliance clinical trials. The ABBR distributes biospecimens for biomarker studies associated with Alliance clinical trials and for secondary studies proposed by the broader cancer research community. Members of the ABBR work with the NCTN and other NCI research networks, contributing scientific leadership to maximize the scientific impact of NCI biospecimen resources. Encompassing multi-PI, multi-institutional pathology and biobanking expertise and hundreds of thousands of high quality, densely annotated biospecimens from several decades of clinical trials, the ABBR represents an unequaled academic resource for translational cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Resource-Related Research Projects--Cooperative Agreements (U24)
Project #
5U24CA196171-02
Application #
9070651
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Lubensky, Irina
Project Start
2015-05-19
Project End
2020-03-31
Budget Start
2016-04-01
Budget End
2017-03-31
Support Year
2
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Washington University
Department
Pathology
Type
Schools of Medicine
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Chumsri, Saranya; Sperinde, Jeff; Liu, Heshan et al. (2018) High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance). Clin Cancer Res 24:3053-3058
Tanioka, Maki; Fan, Cheng; Parker, Joel S et al. (2018) Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. Clin Cancer Res 24:5292-5304
Zaanan, Aziz; Shi, Qian; Taieb, Julien et al. (2018) Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials. JAMA Oncol 4:379-383
Woyach, Jennifer A; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med 379:2517-2528
Gounder, Mrinal M; Mahoney, Michelle R; Van Tine, Brian A et al. (2018) Sorafenib for Advanced and Refractory Desmoid Tumors. N Engl J Med 379:2417-2428
Lei, Jonathan T; Shao, Jieya; Zhang, Jin et al. (2018) Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. Cell Rep 24:1434-1444.e7
Walker, Christopher J; Oakes, Christopher C; Genutis, Luke K et al. (2018) Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA. Leukemia :
Innocenti, Federico; Jiang, Chen; Sibley, Alexander B et al. (2018) Genetic variation determines VEGF-A plasma levels in cancer patients. Sci Rep 8:16332
Innocenti, Federico; Owzar, Kouros; Jiang, Chen et al. (2018) The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation. PLoS One 13:e0202272
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. Leukemia 32:1338-1348

Showing the most recent 10 out of 58 publications